COV (COV) News
Follow COV (COV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Cleo Diagnostics Files Patents For Its Ovarian Cancer Screening Test
Cleo Diagnostics Ltd ASX:COV
NEWS | Sep 30, 2026, 01:37 AM UTC
L
Cascades, Covalon, Sailfish at 52-Week Highs on News
Cascades Inc (T:CAS) Hit a new 52-Week High of $18.31. Cascades this month announced several awards for excellence in leadership, innovation and talent development.Covalon Technologies Ltd (V.COV) Hit a new 52-Week High
NEWS | Sep 28, 2026, 03:21 PM UTC
L
Contamination Protection Solution Highlights Covalon’s Presence at the Association for Vascular Access 2026 Annual Scientific Meeting
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV:COV; OTC:CVALF), an advanced medical technologies company, today announced its participation at the Association for Vascular Access (AVA) Annual Scientific Mee
NEWS | Sep 28, 2026, 11:00 AM UTC
L
Cascades, Chorus, Covalon at 52-Week Highs on News
Cascades Inc. (T.CAS) Hit a new 52-Week High of $18.34. Cascades this month announced several awards for excellence in leadership, innovation and talent development.Chorus Aviation Inc (T.CHR) Hit a new 52-Week High of $
NEWS | Sep 25, 2026, 04:08 PM UTC
L
Big Ridge, Covalon, Founders at 52-Week Highs on News
Big Ridge Gold Corp. (V.BRAU) Hit a 52-Week High of 64 cents. Big Ridge Gold announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, and
COMMODITIES | Sep 24, 2026, 03:02 PM UTC
L
Covalon Technologies Ltd. (COV) RWE Suggests Superior Granulation vs. Peers
Covalon reported retrospective real-world evidence indicating its collagen matrix dressing had the highest probability of >50% granulation at 8 and 12 weeks in diabetic foot ulcers, about 3x the next comparator at 12 wee
NEWS | Sep 24, 2026, 11:00 AM UTC
L
Covalon Reports Encouraging Findings From Real World Evidence Analysis Comparing Collagen Dressings
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced encouraging findings from a retrospective real world evidence analysis of collag
NEWS | Sep 24, 2026, 11:00 AM UTC
L
Thermo Fisher, Bird, BRS at 52-Week Highs on News
Bird Construction Inc. (T.BDT) Hit a new 52-Week High of $83.82. According to, "Bird has delivered exceptional returns over the past several years and is among the top-performing TSX stocks. It has gained more than 155%
NEWS | Sep 23, 2026, 03:21 PM UTC
L
Cleo Diagnostics to start analytical validation of ovarian cancer test
Cleo Diagnostics says it will commence analytical validation of its pre-surgical ovarian cancer blood test after receiving the first production batch of 125 commercial test kits made by US-based Bio-Techne.
EQUITY | Sep 03, 2026, 01:46 AM UTC
L
Cleo Diagnostics receives first batch of manufactured test kits
Cleo Diagnostics Ltd (COV) says it has received its first batch of commercially manufactured test kits.
EQUITY | Sep 02, 2026, 11:52 PM UTC
L
Bravada, Covalon, Fidelity hit 52-week highs on news
Bravada, Covalon, and Fidelity are at 52-week highs on news.
EQUITY | Aug 31, 2026, 03:46 PM UTC
M
COV reports record revenue and profitability
COV said record revenue and profitability were driven by U.S. vascular access and strong gross margins.
EQUITY | Aug 27, 2026, 01:59 PM UTC
L
COV posts record Q3 results on U.S. vascular access growth
COV reported record Q3 results with surging revenue, profit, and margin, led by U.S. vascular access growth.
EARNINGS | Aug 27, 2026, 01:57 PM UTC
M
COV reports rapid Q3 FY'26 revenue and profit growth
COV says Q3 FY'26 delivered rapid revenue and profit growth, led by contamination protection adoption.
EQUITY | Aug 27, 2026, 11:14 AM UTC
M
Covalon Q3 revenue rises; margin expands on hospital adoption
Covalon reported Q3 revenue growth and margin expansion attributed to higher hospital adoption.
EQUITY | Aug 27, 2026, 11:09 AM UTC
M
COV reports Q3 revenue up 20% YoY; gross margin 67.2%
COV said Q3 revenue rose 20% year-over-year. Gross margin was 67.2% and cash increased to $19.4M.
EQUITY | Aug 27, 2026, 11:07 AM UTC
L
Covalon reports fiscal 2026 third-quarter results
Covalon released fiscal 2026 third-quarter results.
EARNINGS | Aug 27, 2026, 11:00 AM UTC